Skip to main content

Table 1 Baseline characteristics of trials

From: Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis

Trial

Analyzed patients

Schedule

End point

Name

Phase

Year

Total

Per arm

Regimen

Drug and dose

primary

secondary

ACCORD12/0405-Prodige 2

III

2010

584

291

OXP-5FU CRT

Cap 1600 mg/mq daily + OXP 50 mg/mq weekly

pCR

CRM, SP, LC,PFS

293

5FU CRT

Cap 1600 mg/mq daily

NSAPB R-04

III

2005

1284

643

OXP-5FU CRT

5FU 225 mg/mq daily or Cap 1650 mg/mq daily + OXP 50 mg/mq weekly

LRC

OS, DFS, TLRR

641

5FU CRT

5FU 225 mg/mq daily or Cap 1650 mg/mq daily

CAO/ARO/AIO-04

III

2006

1236

613

OXP-5FU CRT

5FU 250 mg/mq days 1–14 and 22–35 + OXP 50 mg/mq on days 1,8,22,29

DFS

 

623

5FU CRT

5FU 1000 mg/mq days 1–5 and 29–33

Chinese study

III

2007

206

103

OXP-5FU CRT

Cap 1600 mg/mq days 1–14 and 22–25 + OXP 60 mg/mq on days 1,8,22,29

DFS, OS

 

103

5FU CRT

Cap 1600 mg/mq days 1–14 and 22–25

  1. OXP Oxaliplatin, 5FU 5-fluorouracil, CRT chemoradiotherapy, Cap Capecitabine, pCR pathologic complete response, CRM circumferential rectal margin, SP sphincter preservation, LC local control, PFS progression-free survival, LRC loco-regional control; OS overall survival, DFS disease-free survival, TLRR time to loco-regional recurrence